Large scale ex vivo manufacture of blood cells

Timmins, Nicholas E. and Nielsen, Lars K. (2012). Large scale ex vivo manufacture of blood cells. In Nigel Jenkins, Niall Barron and Paula Alves (Ed.), Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT), Dublin, Ireland, June 7-10, 2009 (pp. 557-571) Dordrecht, Netherlands: Springer.


Author Timmins, Nicholas E.
Nielsen, Lars K.
Title of chapter Large scale ex vivo manufacture of blood cells
Title of book Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT), Dublin, Ireland, June 7-10, 2009
Place of Publication Dordrecht, Netherlands
Publisher Springer
Publication Year 2012
Sub-type Research book chapter (original research)
Series ESACT proceedings
ISBN 9789400708839
9789400708846
Editor Nigel Jenkins
Niall Barron
Paula Alves
Volume number 5
Chapter number 92
Start page 557
End page 571
Total pages 5
Total chapters 119
Collection year 2013
Language eng
Formatted Abstract/Summary
Concerns over the supply and safety of donor blood products have lead to the pursuit of methods with which to manufacture blood cells from haematopoietic stem and progenitor cells (HPC). While several groups have developed protocols theoretically capable of generating multiple units of red blood cells (RBC), these have not yet been demonstrated at a clinically meaningful scale. The large quantities of cells required present a significant challenge due to the correspondingly large culture volumes and cost, and it is questionable if routine manufacture of RBC for general use is feasible. For specialist applications (e.g., transfusion of rare blood phenotypes) however, smaller quantities are required and cost is less of a barrier. In this context, the evolution of scalable bioprocesses for RBC manufacture could be of significant benefit. Similarly, it has been shown that neutrophils can be manufactured from HPC ex vivo, but process yields are below that required for effective management of neutropaenia in chemotherapy patients. Until recently, the best cultivation methods were capable of producing only 1/5th of a dose when starting from umbilical cord blood (UCB) progenitor cells, or a single treatment from granulocyte colony stimulating factor mobilised adult peripheral (mPB) blood. This article examines the challenges associated with the development of clinical scale RBC and neutrophil manufacturing processes, current technologies, and the development of high yield scalable bioprocesses in our own laboratories.
Q-Index Code B1
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Wed, 26 Sep 2012, 09:50:40 EST by Ms Ramona Hooyer on behalf of Aust Institute for Bioengineering & Nanotechnology